IPR
Topic 50 Patentable Subject Matter
Topic 50 — Patentable Subject Matter and Section 3 Exclusions
Section 3 of the Patents Act 1970 lists 16 categories of subject matter that are NOT patentable, even if they otherwise satisfy the novelty and inventive step requirements. The exclusions are public-policy decisions reflecting India's choice to balance patent monopoly against access to fundamental knowledge, ethical concerns, and traditional knowledge protection. The most globally significant — Section 3(d) — is the anti-evergreening provision that prevents trivial pharmaceutical modifications from getting fresh patent protection. The Supreme Court's 2013 judgment in Novartis v. Union of India is the locus classicus on Section 3(d) interpretation. This topic walks through every exclusion in detail, the leading cases, the practical drafting strategies, and the international comparative perspective.
1. The Sixteen Section 3 Exclusions
Sub-section | Exclusion |
|---|---|
Section 3(a) | Frivolous inventions; against natural laws. |
Section 3(b) | Inventions contrary to public order/morality; harmful to health/environment. |
Section 3(c) | Mere discovery of scientific principle / abstract theory / natural substance. |
Section 3(d) | New form of known substance without enhanced efficacy; new property/use of known substance; new use of known process. |
Section 3(e) | Mere admixture without synergistic effect. |
Section 3(f) | Mere arrangement / rearrangement of known devices. |
Section 3(g) | [Repealed by 2002 Amendment] |
Section 3(h) | Method of agriculture / horticulture. |
Section 3(i) | Method of treatment of humans/animals (medical/surgical/curative/diagnostic/therapeutic). |
Section 3(j) | Plants/animals; essentially biological processes; microorganisms (special rules). |
Section 3(k) | Mathematical / business methods; computer programs per se; algorithms. |
Section 3(l) | Literary / dramatic / musical / artistic works. |
Section 3(m) | Mere scheme / rule / method of performing mental act / playing game. |
Section 3(n) | Presentation of information. |
Section 3(o) | Topography of integrated circuits. |
Section 3(p) | Inventions effectively traditional knowledge. |
2. Sections 3(a) to 3(c) — General Exclusions
A. Section 3(a) — Frivolous and Anti-Natural Inventions
Section 3(a) "An invention which is frivolous or which claims anything obviously contrary to well established natural laws." |
Section 3(a) excludes "perpetual motion machines", devices claiming to violate thermodynamics, and frivolous inventions lacking serious technical content. The exclusion is largely uncontroversial — no patent office grants such patents.
B. Section 3(b) — Public Order and Morality
Section 3(b) "An invention the primary or intended use or commercial exploitation of which could be contrary to public order or morality or which causes serious prejudice to human, animal or plant life or health or to the environment." |
Section 3(b) excludes inventions whose primary use harms public order, morality, life, health or environment. Examples:
- Methods of human cloning.
- Inventions designed to facilitate criminal activities (e.g., counterfeiting devices).
- Inventions for chemical/biological warfare beyond defensive purposes.
- Methods that involve cruelty to animals beyond medical research norms.
C. Section 3(c) — Mere Discovery
Section 3(c) "The mere discovery of a scientific principle or the formulation of an abstract theory or discovery of any living thing or non-living substance occurring in nature." |
Section 3(c) excludes "discoveries" — finding what already exists in nature — distinguishing them from "inventions" which apply discoveries to practical effect. Examples:
- Discovery of a new chemical element.
- Discovery of a new microorganism in soil.
- Discovery of a natural substance in a plant.
- A theoretical formula for predicting weather (until reduced to a practical method).
✅ Section 3(c) — discovery vs. invention The discovery/invention distinction is one of the oldest in patent law. A "discovery" is finding something that already exists; an "invention" is applying a discovery to create something new. The mathematical proof of Fermat's Last Theorem is a discovery (and excluded under Section 3(c)); a software algorithm that uses related number theory to optimise data compression may be an invention (subject to Section 3(k) computer-program-per-se exclusion). The line between discovery and invention is sometimes blurred — particularly in biotech, where the isolation and purification of natural substances raises questions whether the resulting product is a "natural substance" or an "invented" compound. |
3. Section 3(d) — The Anti-Evergreening Provision
Section 3(d) "The mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or of the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant. Explanation — For the purposes of this clause, salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substance shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy." |
A. Three Sub-Categories
1 NEW FORM no enhanced efficacy | 2 NEW PROPERTY/USE of known substance | 3 NEW USE OF KNOWN PROCESS unless new product |
- Section 3(d) limb 1 — "new form" of known substance not enhancing efficacy. Targets the typical evergreening pattern of patenting trivial reformulations.
- Section 3(d) limb 2 — "new property" or "new use" of known substance. Targets the patenting of newly-discovered uses of existing drugs.
- Section 3(d) limb 3 — "new use of known process" unless the use produces a new product. Targets process-patent extensions.
B. The Explanation
The Explanation is critical. It deems various pharmaceutical formulation variants to be the SAME substance unless they differ significantly in efficacy. The list includes:
- Salts
- Esters
- Ethers
- Polymorphs
- Metabolites
- Pure form
- Particle size variations
- Isomers and mixtures of isomers
- Complexes and combinations
✅ Why the Explanation matters Without the Explanation, pharmaceutical companies could file separate patents on each polymorph, salt, isomer, particle size, etc. of an active pharmaceutical ingredient — extending the effective monopoly far beyond the 20-year term of the original patent. The Explanation deems these variants to be "the same substance" unless they differ significantly in efficacy. This forecloses the standard pharmaceutical evergreening playbook. |
C. Novartis v. Union of India — The Locus Classicus
📖 Novartis AG v. Union of India, (2013) 6 SCC 1 Facts — Novartis applied for a patent on the beta-crystalline form of imatinib mesylate (marketed as Glivec/Gleevec, a chronic myeloid leukemia drug). The Indian Patent Office refused under Section 3(d). Novartis appealed through writ petition to Madras High Court (where it also challenged constitutional validity of Section 3(d)), then to IPAB, then via Article 136 SLP to the Supreme Court. Holding — Justice Aftab Alam and Justice Ranjana Prakash Desai of the Supreme Court (1 April 2013) rejected Novartis's appeal. Key holdings: (i) "Efficacy" in pharmaceuticals means "therapeutic efficacy" — the ability to produce desired therapeutic effect. (ii) Increased bioavailability (30% in this case) is not enhanced therapeutic efficacy. (iii) Section 3(d) sets a "second tier" of patentability standards specifically for chemical substances/pharmaceuticals to prevent evergreening while leaving the door open for genuine inventions. (iv) The provision is constitutionally valid; not violative of Article 14; not in conflict with TRIPS. Significance — Globally cited for India's anti-evergreening framework. Established that: · Section 3(d) sets a "higher standard" than ordinary inventive step. · Therapeutic efficacy is the operational measure for pharmaceuticals. · India exercises Article 27 TRIPS flexibility within the bounds of the agreement. · Inspired similar provisions in South Africa, Argentina, Philippines and other developing countries. |
4. Sections 3(e) and 3(f) — Admixture and Arrangement
A. Section 3(e) — Mere Admixture
Section 3(e) "A substance obtained by a mere admixture resulting only in the aggregation of the properties of the components thereof or a process for producing such substance." |
Section 3(e) excludes mere admixtures whose properties are merely the sum of the components' properties. Patentability requires synergistic effect — the combination must produce a result greater than the sum of the parts. Pharmaceutical fixed-dose combinations may face Section 3(e) challenges unless synergy is demonstrated.
B. Section 3(f) — Mere Arrangement
Section 3(f) "The mere arrangement or re-arrangement or duplication of known devices each functioning independently of one another in a known way." |
Section 3(f) excludes "kits" or assemblies of known components functioning independently. Patentability requires that the combination produce a unified, integrated result — not merely that the components be juxtaposed.
5. Sections 3(h) and 3(i) — Agriculture and Medical Treatment
A. Section 3(h) — Agriculture and Horticulture
Section 3(h) "A method of agriculture or horticulture." |
Section 3(h) excludes agricultural methods. The exclusion serves food security — methods of growing crops should remain in the public domain. However, the exclusion does not cover:
- Plant varieties (covered by PPV&FR Act 2001).
- Agricultural machinery and equipment.
- Agricultural chemicals and fertilisers.
B. Section 3(i) — Methods of Medical Treatment
Section 3(i) "Any process for the medicinal, surgical, curative, prophylactic, diagnostic, therapeutic or other treatment of human beings or any process for a similar treatment of animals to render them free of disease or to increase their economic value or that of their products." |
Section 3(i) excludes methods of medical treatment. The exclusion serves access to healthcare — doctors should not need licences to use treatment methods. However, the exclusion does not cover:
- Pharmaceutical compounds and compositions.
- Medical devices and surgical instruments.
- Diagnostic kits and reagents.
- Methods of manufacturing pharmaceuticals.
6. Section 3(j) — Plants, Animals and Biological Processes
Section 3(j) "Plants and animals in whole or any part thereof other than micro-organisms but including seeds, varieties and species and essentially biological processes for production or propagation of plants and animals." |
Section 3(j) excludes:
- Plants and animals in whole or part — except microorganisms.
- Seeds, varieties and species — covered by PPV&FR Act 2001.
- Essentially biological processes for production/propagation.
✅ Microorganisms — the exception Section 3(j) explicitly EXCEPTS microorganisms from the plant-animal exclusion. Genetically modified microorganisms, novel bacterial strains, recombinant viruses, and isolated cellular components can therefore be patented if they meet other patentability requirements. The Budapest Treaty 1977 (India acceded 2001) provides for international deposit of microorganisms in approved depositories. The Indian Type Culture Collection serves as one such authority. |
7. Section 3(k) — Mathematical Methods, Software, Algorithms
Section 3(k) "A mathematical or business method or a computer programme per se or algorithms." |
A. The "Per Se" Qualifier
Section 3(k) excludes computer programs "per se" — but the qualifier matters. The Indian Patent Office Manual of Patent Practice and Procedure 2019 clarifies that:
- Pure software claims (program code as such) are NOT patentable.
- Software embedded in hardware that produces a technical effect MAY BE patentable.
- Software-implemented inventions that solve a technical problem in a non-obvious way MAY BE patentable.
B. Indian Position on Software Patents
Indian software-patent jurisprudence is restrictive compared to the US (post-Alice Corp 2014) but more permissive than the EU. The Patent Office Guidelines on Computer-Related Inventions (CRI Guidelines, revised 2017) require:
- Technical contribution beyond software per se.
- Hardware integration or technical effect.
- Solution to a technical problem (not merely business or mental).
8. Sections 3(l) to 3(p) — Other Exclusions
- Section 3(l) — literary, dramatic, musical, artistic works (covered by Copyright Act 1957).
- Section 3(m) — mere scheme/rule/method of mental act/playing game (excludes board games qua games; covers software games via Section 3(k)).
- Section 3(n) — presentation of information (covers data displays, signage, charts).
- Section 3(o) — topography of integrated circuits (covered by SICLD Act 2000).
- Section 3(p) — inventions effectively traditional knowledge (Topic 88-90 of master spine cover this in detail).
✅ Section 3(p) — traditional knowledge protection Section 3(p) excludes "an invention which in effect, is traditional knowledge or which is an aggregation or duplication of known properties of traditionally known component or components." This provision protects India's vast pool of traditional knowledge — Ayurveda, Yoga, Siddha, Unani, traditional agricultural practices — from being patented as "inventions" by foreign or domestic actors. The Traditional Knowledge Digital Library (TKDL) — a project of CSIR and AYUSH Ministry — documents traditional knowledge in machine-readable form to support Section 3(p) examinations and prevent "biopiracy". |
9. Practical Drafting Strategies for Section 3
✅ Twelve drafting points for Section 3 challenges For Section 3(d) pharmaceutical applications, demonstrate enhanced therapeutic efficacy (not just bioavailability or stability). Provide comparative data: efficacy of new form vs known substance — preferably clinical or in vivo evidence. For Section 3(e) admixtures, demonstrate synergistic effect with experimental data. For Section 3(f) arrangements, show integrated function rather than mere juxtaposition. For Section 3(i) excluded medical methods, frame the claim as a product (composition, device) rather than a process. For Section 3(j) biotech, leverage the microorganism exception — claim genetically modified organisms specifically. For Section 3(k) software, claim hardware-software integration; demonstrate technical effect. For Section 3(p) traditional knowledge, search the TKDL before filing; document genuine technical advance over the traditional knowledge. For pharmaceutical applications, provide efficacy comparison data alongside the application — pre-empts Section 3(d) challenges. For Markush claims (chemical genus), be cautious about Section 3(d) — claims that claim large families may be vulnerable. Draft specifications with sufficient enabling disclosure — supports patentability and defends against revocation. For dual-track filings (PCT national phase + Indian filing), tailor Indian claims to Section 3 considerations during drafting. |
🎯 EXAM POINTERS — TOPIC 50
|